Treatment Updates in Acute Myeloid Leukemia

Advances in the molecular understanding of acute myeloid leukemia (AML) has enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for improved therapeutic approaches to refine posttreatment risk stratification and expand the treatment options for patients with AML who have unfavorable cytogenetics or experience poor outcomes. Some novel treatment options are associated with improved clinical outcomes and fewer side effects than the conventional standard regimens. In most cases, there are unique adverse effects that require specialized supportive care measures. Informing clinicians about these therapeutic advances and necessary supportive care precautions will aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations.

Target Audience

The program is designed to meet the needs and improve the competence and performance of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals who manage the care of patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Evaluate novel and emerging treatment strategies for acute myeloid leukemia (AML) and integrate them into the management of appropriate patients.
  • Compare and contrast factors used for posttreatment risk stratification in AML.
  • Summarize supportive care considerations for novel and emerging AML therapies. 
Additional information

This activity is supported by educational grants from:

  • Abbott's molecular business
  • Adaptive Biotechnologies
  • AstraZeneca
  • BeiGene, Ltd.
  • Blueprint Medicines
  • Daiichi Sankyo
  • Deciphera Pharmaceuticals
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • Gilead Sciences
  • GlaxoSmithKline
  • GRAIL, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
  • Lilly
  • Olympus Corporation of the Americas
  • Novartis
  • Pfizer
  • Puma Biotechnology
  • Seagen Inc. formerly Seattle Genetics
  • Taiho Oncology, Inc.
  • TeSera Therapeutics

This activity is supported by independent medical education grants from: 

  • Bristol Myers Squibb 
  • Illumina, Inc. 
  • Regeneron Pharmaceuticals, Inc and Sanofi Genzyme

This activity is supported by independent educational grants from:

  • AbbVie
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Incyte
  • Merck & Co., Inc.

This activity is supported by educational funding provided by Amgen.

This educational activity is supported by a medical education grant from Exelixis, Inc. & Karyopharm® Therapeutics.

This project has been made possible in part by a grant from Varian Medical Systems/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Course opens: 
Course expires: 

Alexander E. Perl, MD, MS
Abramson Cancer Center at the University of Pennsylvania


NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care.  Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. 


NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.

NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships: 

Alexander E. Perl, MD, MS
AbbVie, Inc.: Scientific Advisor; Grant/Research Support; Consulting Fee; Honoraria
Actinium Pharmaceuticals: Scientific Advisor; Honoraria
Astellas Pharma US, Inc.: Scientific Advisor; Grant/Research Support; Consulting Fee; Honoraria
BeatAML LLC: Consulting Fee
Celgene Corporation: Scientific Advisor; Honoraria
Daiichi-Sankyo Co.: Scientific Advisor; Grant/Research Support; Consulting Fee; Honoraria
Forma Therapeutics: Consulting Fee
Fujifilm Corporation: Grant/Research Support
Genentech, Inc.: Scientific Advisor; Honoraria
Loxo Oncology, Inc.: Scientific Advisor; Honoraria
Sumitomo Dainippon: Scientific Advisor; Honoraria
Syndax: Scientific Advisor; Honoraria 

Moderator Disclosures

The faculty listed below discloses the following relevant financial relationships: 

Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Scientific Advisor
Aprea: Scientific Advisor
Astellas Pharma US, Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Foghorn: Scientific Advisor
Genentech, Inc.: Scientific Advisor
Gilead Sciences, Inc.: Scientific Advisor
GlycoMimetics, Inc.: Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor
Kiadis: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Syndax: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

NCCN Staff Disclosures

The NCCN Leadership listed below discloses no relevant financial relationships:

Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:

Mallory Campbell, PhD; Liz Hollinger, RN, BSN; Ndiya Ogba, PhD (Employed by NCCN until January 12, 2021); Hema Sundar, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 0.75 contact hour.

NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-063-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing